"Biostimulators" and "collagen biostimulator" are searched about 3,000 times a month in the US, with "Radiesse biostimulator" adding several hundred more (clickstream estimate, October 2026). The word covers a growing family of injectables that share one idea — change the face slowly through the body's response to injected particles — but differ in material, regulatory status and evidence. This page sorts them, as of 11 October 2026, and points to the detailed pages on this site. It is not a recommendation for any product.
The materials, sorted by FDA status
| Material | Example products | US status (openFDA, 11 Oct 2026) |
|---|---|---|
| Poly-L-lactic acid (PLLA) | Sculptra | approved, PMA P030050: HIV facial fat loss (2004), nasolabial folds and facial wrinkles (2009), cheek wrinkles (2023) |
| Calcium hydroxylapatite (CaHA) | Radiesse, Radiesse (+) | approved, PMA P050052 and P050037: facial folds and HIV fat loss (2006), hands (2015), jawline (2021), diluted 1:2 for décolleté wrinkles (2026) |
| PMMA microspheres in bovine collagen | Bellafill, renamed SANAE in August 2026 | approved as a filler (PMA P020012, 2006); semi-permanent, sometimes grouped with biostimulators |
| Polycaprolactone (PCL) | Ellansé | no premarket approval; no US device listing |
| Poly-D,L-lactic acid (PDLLA) | Juvelook | no premarket approval; no US device listing |
| CaHA with hyaluronic acid (hybrid) | HArmonyCa | no premarket approval; no US device listing, but 108 device reports |
"No premarket approval" is a statement about the US record, not about other countries, where several of these products are sold under their own regulators. The 108 FDA reports naming HArmonyCa, filed from 2022 (3 that year, 23 in 2023, 34 in 2024, 28 in 2025 and 20 so far in 2026), show that events involving it reach FDA's database even without a US approval; reports can be filed by manufacturers about events abroad.
The detailed pages
- Sculptra (PLLA): what it is, its three approvals and the 2023 delayed-inflammation labelling — Sculptra explainer; what a session cost in the national surveys and how many vials the trials used — Sculptra cost; off-label body use and its reports — Sculptra on the buttocks.
- Sculptra against Radiesse: the two approved stimulators compared on particles, approvals, funding of the head-to-head studies and device reports — Sculptra vs Radiesse.
- Stimulators against hyaluronic-acid fillers: the randomized trials over 4 to 120 weeks and why only HA can be dissolved — Sculptra vs filler.
- Fillers that really were collagen: the 1981 bovine collagen implants, the skin test and the one collagen-containing filler still approved — collagen injections.
- Skin boosters (polynucleotides, PDRN, intradermal hyaluronic acid), a different category often sold beside these — skin boosters.
How fast the term has grown
The word is newer in the literature than the products. A PubMed search for biostimulator terms in an aesthetic, skin or collagen context, run on 11 October 2026, returned 468 records: 90 published in all years up to 2014, then:
| Year | Records |
|---|---|
| 2010 | 8 |
| 2015 | 13 |
| 2018 | 16 |
| 2020 | 21 |
| 2022 | 17 |
| 2023 | 39 |
| 2024 | 67 |
| 2025 | 89 |
| 2026 (to 11 Oct) | 109 |
The count roughly doubled each year from 2022 to 2024, and 2026 had already passed 2025 by October. More records mean more attention, not stronger evidence: many are reviews, consensus statements and case series rather than controlled trials.
What "collagen stimulator" claims, and what it does not
No biostimulator contains collagen. The name describes a mechanism: particles placed under the skin provoke a tissue response that includes new collagen, and the visible change follows over months. The evidence for that mechanism is of two kinds. Trials score appearance — wrinkle and volume scales, read by blinded evaluators — at intervals after treatment. Laboratory and biopsy studies look at tissue and gene expression, and here funding matters: the randomized gene-expression studies comparing PLLA with CaHA were run by authors from one maker and a particle study by authors from its competitor, and each found the other product more inflammatory. That pattern is set out in Sculptra vs Radiesse.
Two shared limits follow from the materials themselves. None can be dissolved — hyaluronidase breaks down hyaluronic acid, not these polymers or minerals — and all depend on the injector: dilution, depth and placement are chosen by the clinician, and several of the body and diluted uses promoted by clinics sit outside the US approvals.
Comparisons between materials
Published comparisons beyond PLLA and CaHA are mostly laboratory work. A 2025 laboratory study compared the physical and chemical properties of Sculptra with three PDLLA-based fillers, including Juvelook, and found differences in particle shape and composition between brands sold under the same broad material class (PMID 41516868). A 2020 review described polycaprolactone's path from surgical sutures to an aesthetic collagen stimulator (PMID 32161484), and a 2024 Italian retrospective study reported real-world use of HArmonyCa (PMID 39360597). PubMed returned 21 records naming Ellansé, 18 naming Juvelook and 18 naming HArmonyCa on 11 October 2026 — small literatures compared with Sculptra or Radiesse.
What is and is not established
Established: two biostimulators, Sculptra and Radiesse, are FDA-approved for specific uses; polycaprolactone, PDLLA and hybrid products had no US premarket approval on 11 October 2026; none contains collagen; none can be dissolved; the literature using the term has grown several-fold since 2022.
Not established: how the unapproved materials compare with the approved ones in controlled human trials; how much new collagen any product produces in a given person; and whether faster growth in publications reflects better evidence. Choosing whether to use any of them is a conversation with a board-certified clinician.
Sources
- US FDA, Premarket Approval database via openFDA
device/pma, queried 2026-10-11:P030050(Sculptra; approvals 2004-08-03, 2009-07-28, 2023-04-25);P050052andP050037(Radiesse; 2006-12-22 and later indications as given on our Sculptra vs Radiesse page, including S162, 2026-03-31);P020012(Bellafill/SANAE); trade-name searches for ellanse, harmonyca, juvelook, gouri, lenisna (0 records each). - US FDA, Global Unique Device Identification Database via openFDA
device/udi, queried 2026-10-11 by brand name: ellanse, harmonyca, juvelook (0 each); sculptra (12), radiesse (14). - US FDA, MAUDE via openFDA
device/event, queried 2026-10-11:device.brand_name:harmonyca(108; counted by year of receipt), ellanse (1). - Christen MO, Vercesi F. Polycaprolactone: how a well-known and futuristic polymer has become an innovative collagen-stimulator in esthetics. Clin Cosmet Investig Dermatol 2020;13:31-48. PMID 32161484.
- Su CY, Chang YC, Cheng PJ, Fang HW. Comparative physicochemical characterization of polylactic acid-based dermal fillers. Polymers (Basel) 2025;18(1):84. PMID 41516868.
- Proietti I, Spagnoli A, Favaroni A, et al. HArmonyCa hybrid filler to restore connective tissue: an Italian real-life retrospective study. J Cosmet Dermatol 2024;23(12):3883-92. PMID 39360597.
- PubMed E-utilities searches, 2026-10-11:
biostimulat*[tiab] AND (filler*[tiab] OR aesthetic*[tiab] OR skin[tiab] OR collagen[tiab])(468; by publication year as tabled; 90 to 2014);ellanse[tiab] OR ellansé[tiab](21);juvelook[tiab](18);harmonyca[tiab](18).